Duritect™
Information for patients and caregivers
A family of blood tests that quickly and accurately assesses your risk of Alzheimer’s or Parkinson’s disease, so you can get to a diagnosis sooner.1,2
blood test 1,2
invasive
(within 48–72h*)
understand
Start your journey to a
diagnosis with DuritectTM
If you or someone you care for is suspected to be at risk of a neurodegenerative disease, understanding the probability of having the disease could help you get on the right path to a diagnosis earlier.3,4
Duritect™ combines a simple blood test with machine learning analysis to provide a clear and easy-to-understand risk score for Alzheimer’s disease (AD) or Parkinson’s disease (PD) – so that you and your doctor can decide what to do next.1,2
The benefits of
getting tested
A quicker path to a diagnosis
More time to prepare for what lies ahead
the future.4-7
A chance to start treatment and make changes earlier
slow disease progression.4,7
What an early
diagnosis enables
Early diagnosis of Alzheimer’s or Parkinson’s can give you the chance to manage the disease more effectively and improve your overall quality of life.4,7
You could explore treatment options under the guidance of your physician. You may, for example, be able to get access to available drugs earlier, take part in clinical trials, or utilize alternative therapies.3,4
When Alzheimer’s or Parkinson’s diseases are still in their early stages, making lifestyle changes like becoming more active, eating healthier, and improving your sleep patterns could be beneficial.4,7,8
An early diagnosis could also help you to plan for the future by seeking financial guidance and obtaining legal advice. Also, accessing psychological and social support early on could help you to better cope with the disease going forward.4-7
If you’ve been prescribed Duritect™, getting tested could help you move forward on your healthcare journey. Find out more about our tests for Alzheimer’s disease or Parkinson’s disease, including what to expect from the process.
Abbreviations and references
* Delays due to shipping / delivery of samples to the laboratory may impact the turnaround time for results.
References
- [Duritect-AD™. Indications for use. Durin Life Sciences. 2024.]
- [Duritect-PD™. Indications for use. Durin Life Sciences. 2024.]
- DeMarshall CA, Viviano J, Emrani S, et al. Early detection of Alzheimer’s disease-related pathology using a multi-disease diagnostic platform employing autoantibodies as blood-based biomarkers. J Alzheimer’s Dis. 2023;92:1077–1091.
- Nasreddine Z, Garibotto V, Kyaga S, Padovani A. The early diagnosis of Alzheimer's disease: a patient-centred conversation with the care team. Neurol Ther. 2023;12:11–23.
- Gaster B, Pope TM. Guiding the future: rethinking the role of advance directives in the care of people with dementia. Hastings Cent Rep. 2024:54 (Suppl 1):S33-S39. doi: 10.1002/hast.1553.
- Siwik CJ, Phillips K, Litvan I, et al. A pilot randomized controlled trial investigating MBSR for Parkinson’s disease patients and their caregiving partners: effects on distress, social support, cortisol, and inflammation. Mindfulness. 2022;13:1271–1280.
- Rasmussen J, Langerman H. Alzheimer’s disease – why we need early diagnosis. Degen Neurol Neuromusc Dis. 2019;9:123–130.
- Arora S, Santiago JA, Bernstein M, Potashkin JA. Diet and lifestyle impact the development and progression of Alzheimer’s dementia. Front Nutr. 2023;10:1213223